Bethany Sensenig - 02 Nov 2026 Form 4 Insider Report for Supernus, Inc. (INDV)

Reporting relationship: Director
Issuer ticker: INDV
Reported as of: 02 Nov 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Nov 2026, 17:58:08 UTC
Prior SEC filing: 11 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Timothy C. Dec, as attorney-in-fact

Filing notes and source

Key filing fact

Bethany Sensenig filed Form 4 for Supernus, Inc. (INDV) on 04 Nov 2026.

Key facts

This page summarizes Bethany Sensenig's Form 4 filing for Supernus, Inc. (INDV).
5 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 04 Nov 2026, 17:58.

Change

Previous filing in this sequence was filed on 11 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001899935 Primary reporting owner

Sensenig Bethany

Relationship: Director
Address: C/O SUPERNUS, INC., 9715 KEY WEST AVENUE, ROCKVILLE
Signature: /s/ Timothy C. Dec, as attorney-in-fact
Signature date: 04 Nov 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INDV transaction Derivative

Restricted Stock Units

Other

Transaction value
Shares: +4,603
Change %
Price: $0.000000^*
Shares after: 4,603
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,603
Exercise price: $0.000000
Footnotes: F1, F2

INDV transaction Derivative

Director Stock Option (right to buy)

Other

Transaction value
Shares: +37,198
Change %
Price: $0.000000^*
Shares after: 37,198
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 37,198
Exercise price: $19.63
Footnotes: F1

INDV transaction Derivative

Director Stock Option (right to buy)

Other

Transaction value
Shares: +12,708
Change %
Price: $0.000000^*
Shares after: 12,708
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,708
Exercise price: $18.15
Footnotes: F1

INDV transaction Derivative

Director Stock Option (right to buy)

Other

Transaction value
Shares: +11,236
Change %
Price: $0.000000^*
Shares after: 11,236
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,236
Exercise price: $21.77
Footnotes: F1

INDV transaction Derivative

Director Stock Option (right to buy)

Other

Transaction value
Shares: +7,665
Change %
Price: $0.000000^*
Shares after: 7,665
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,665
Exercise price: $32.60
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except that performance stock unit awards were converted into time-vesting restricted stock units.

Footnote F2

These restricted stock units are settled in common stock upon vesting, which occurs on February 18, 2027.